Cloudbreak Therapeutics Advances CBT-004 to Phase 3 Trials Following Successful FDA Meeting for Vascularized Pinguecula Treatment
Key Insights
Cloudbreak Therapeutics (search) received FDA clearance to advance CBT-004, a first-in-class multi-kinase inhibitor eye drop, to Phase 3 trials for vascularized pinguecula (search) treatment following a successful End-of-Phase 2 meeting on December 10, 2025.
The Phase 2 trial demonstrated that CBT-004 met its primary efficacy endpoint for conjunctival hyperemia (search) reduction and showed statistically significant improvements across multiple secondary endpoints compared to placebo.
CBT-004 targets an unmet medical need as there are currently no FDA-approved treatments for vascularized pinguecula (search), a common conjunctival condition that causes ocular discomfort and inflammation.
Cloudbreak Therapeutics (search) LLC, a wholly-owned subsidiary of Cloudbreak Pharma Inc (search)., has received FDA clearance to advance its investigational ophthalmic drug CBT-004 to Phase 3 clinical trials following a successful End-of-Phase 2 meeting held on December 10, 2025. The multi-kinase inhibitor represents a potential first-in-class treatment for vascularized pinguecula (search), addressing a significant unmet medical need in ophthalmology.
Promising Phase 2 Results Drive FDA Approval
CBT-004 demonstrated strong safety and efficacy signals in its recently completed Phase 2 clinical trial, which commenced in December 2023 and concluded in May 2025. The study evaluated three patient groups: a high-dose CBT-004 group, a low-dose CBT-004 group, and a placebo group.
According to preliminary data analysis reported in April 2025, CBT-004 met its primary efficacy endpoint of conjunctival hyperemia (search) reduction. Both CBT-004 treatment groups showed statistically significant reductions in conjunctival hyperemia scores versus the placebo group, with a clear dose-response relationship observed. The high-dose CBT-004 group performed better than the low-dose group, and multiple secondary efficacy endpoints also demonstrated statistically significant differences between both CBT-004 groups and placebo.
The drug demonstrated an excellent ocular safety profile and was well tolerated across all study participants. Cloudbreak finalized the clinical trial report in July 2025, which formed the basis for the FDA meeting discussions.
Addressing Unmet Medical Need in Vascularized Pinguecula
Vascularized pinguecula (search) presents as a round, yellowish, elevated tissue that manifests on the conjunctiva adjacent to the cornea. The condition's prevalence increases with both advancing age and ultraviolet exposure, causing symptoms including ocular discomfort, pain, foreign body sensation, tearing, itching, and redness.
Currently, no FDA-approved treatments exist for vascularized pinguecula (search). Common treatment methods include surgery and prescription steroid eye drops to relieve symptoms, but these approaches do not specifically target the underlying pathophysiology.
Novel Mechanism of Action
CBT-004 is formulated as a topical ophthalmic eye drop containing a multi-kinase inhibitor that targets vascular endothelial growth factor receptors (search) (VEGFRs) and platelet-derived growth factor receptors (search) (PDGFRs). This mechanism is designed to reduce abnormal conjunctival vascularity and related inflammation associated with vascularized pinguecula (search).
Preclinical studies demonstrated good effectiveness and safety in non-clinical animal disease models and toxicological tests, supporting the transition to human clinical evaluation.
Strategic Implications for Cloudbreak
The FDA's confirmation of CBT-004's drug safety and efficacy represents a significant milestone in the asset's development trajectory. The company considers this meeting crucial for addressing potential Phase 3 clinical trial plans and New Drug Application requirements.
This development marks a significant step toward the commercialization of CBT-004 and could potentially advance Cloudbreak's position in the ophthalmic pharmaceutical market. The company has not yet released specific details regarding the Phase 3 trial timeline or design.
Cloudbreak Pharma Inc (search)., headquartered in Irvine, California, is a clinical-stage global biotechnology company focused on developing pipeline candidates targeting anterior- and posterior-segment ocular diseases, including juvenile myopia, meibomian gland dysfunction, presbyopia, and vascularized pinguecula (search).